Abstract:Abstract Purpose Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is primarily treated with trastuzumab and other HER2-targeted therapies. However, approximately 30% of HER2-positive tumors exhibit de novo resistance, whereas 40% acquire resistance to these therapies. The mechanisms underlying drug resistance are unclear, and a better understanding of acquired resistance to HER2-targeted therapy is essential for the development of more effective therapeutics. Methods We enrolled 11 patients with HER2-positive breast cancer, all of whom had been treated with trastuzumab for one year and developed lung metastasis in the follow-up. We conducted exome sequencing of the primary and paired metastatic tumors from four patients. We identified somatic mutations in HER2 (K753E and L755S) affecting the kinase domain only in the metastatic lesions of two cases. Sanger sequencing was performed to analyze all exons of the HER2 gene in the paired primary and metastatic tumors of the remaining seven cases. Furthermore, we enrolled 48 patients with HER2-positive disease who underwent trastuzumab-based neoadjuvant therapy. We performed Sanger sequencing of the HER2 gene in paired tumor DNA before and after neoadjuvant therapy. To determine the phenotype of these mutations, we functionally characterized the HER2 mutations using protein structure analysis, in vitro kinase assays, cell culture, and xenograft experiments. Results We identified somatic mutations in HER2 affecting the kinase domain in four of 11 metastatic tumors (one case with K753E and three cases with L755S). None of the primary tumors harbored HER2 mutations. Furthermore, Sanger sequencing in the neoadjuvant setting revealed two of 48 cases harboring HER2 mutations (K753E and L755S) in the post-treatment samples, none of whom had any HER2 mutation in the paired pre-treatment tumor. Protein structure visualization hinted that the HER2 L753 and L755 side chains were in close proximity to the binding site for small-molecule inhibitors, indicating mutations at this residue might produce drug resistance. In vitro kinase assays revealed that HER2 K753E had greater tyrosine kinase-specific activity than wild-type. HER2 autophosphorylation, phosphorylation of HER2’s dimerization partners (EGFR or HER3) and downstream signaling proteins were significantly upregulated in MCF10A and MCF7 cells overexpressing HER2 K753E or L755S. Trastuzumab or lapatinib treatment did not decrease the number of colonies formed in MCF10A cells transduced with K753E or L755S. MCF7 cells bearing K753E or L755S mutant could reverse the inhibition of lapatinib in xenografts. The MCF10A-HER2 K753E and L755S cells were resistant to trastuzumab (IC50>1000μg/mL) and lapatinib (IC50>10μmol/L) but could be readily inhibited by neratinib (IC50 of 15 nmol/L), an irreversible kinase inhibitor of HER2. Conclusion These data implicate that mutations in HER2 kinase domain are a key mechanism in resistance to HER2-targeted therapy. The selection of functional HER2 mutations might act as potential drivers of trastuzumab resistance during the progression of HER2-positive disease. Furthermore, more potent HER2 inhibitors such as neratinib might be of therapeutic benefit for trastuzumab-resistant breast cancer. Citation Format: Yizhou Jiang, Ke-Da Yu, Wen-Jia Zuo, Yu-Jie Wang, Zhi-Ming Shao. Exome sequencing identified emergence of HER2 kinase domain mutations in trastuzumab-resistant breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-04-02.

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients

Tumor Exome Sequencing and Copy Number Alterations Reveal Potential Predictors of Intrinsic Resistance to Multi-Targeted Tyrosine Kinase Inhibitors

Whole-exome Sequencing Reveals Potential Mechanisms of Drug Resistance to FGFR3-TACC3 Targeted Therapy and Subsequent Drug Selection: Towards a Personalized Medicine.

Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer

Identification of KLK10 As a Therapeutic Target to Reverse Trastuzumab Resistance in Breast Cancer.

Abstract P1-04-02: Exome Sequencing Identified Emergence of HER2 Kinase Domain Mutations in Trastuzumab-Resistant Breast Cancer

Deciphering the Impact of Rare Missense Variants in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer through Whole Exome Sequencing: A Computational Approach

Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data

Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer

Whole Genome Sequencing in single CTC improves clinical outcome in Her-2 negative breast cancer patients

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy

Analysis of Different HER‐2 Mutations in Breast Cancer Progression and Drug Resistance

Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape

Estrogen receptor—positive breast cancer survival prediction and analysis of resistance–related genes introduction

Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug‐Resistant Model and Genome‐Wide siRNA Screening

Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

The prognostic genes model of breast cancer drug resistance based on single-cell sequencing analysis and transcriptome analysis

Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC

Survival prediction and analysis of drug-resistance genes in HER2-positive breast cancer

Identification of exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen.

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA